Menu
Menu
The future of precision medicine is coming to San Sebastián!
The EMEA Innovation Summit by SOPHiA GENETICS explores how precision medicine is scaling today, and what breakthroughs will shape clinical care tomorrow.
Following the success of our 2025 edition in Rolle, we’re thrilled to host the next SOPHiA GENETICS Innovation Summit at the iconic Real Sociedad Arena, a venue that captures the energy, innovation, and collaboration that define our community.
This year’s agenda is set to dive deep into innovation, from AI-driven discovery and liquid biopsy advancements to collaborative approaches in oncology and clinical genomics. Expect thought-provoking sessions, impactful discussions, and cross-industry networking designed to accelerate innovation in healthcare.
Over two days, the event brings together:
Together, we connect insights with real-world impact bridging today’s scalable platforms with tomorrow’s clinical breakthroughs.
The day will begin with a focus on scalability and operational maturity, tackling the growing challenges of data volume and complexity while building robust end-to-end workflows. Through AI-driven insights, we’ll explore how to accelerate the global adoption of precision medicine. In the afternoon, the spotlight shifts to future-facing clinical innovation, diving into next-generation data modalities and their applications across solid tumors, liquid biopsy, blood cancers, and germline analysis. Bringing it all together, the sessions highlight real-world clinical studies, emerging technologies, and pharma perspectives, showcasing how advanced analytics are translating into meaningful clinical impact.
Fill out the form to secure your spot!
Do you have any questions or require further assistance? Please get in touch with us!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
